Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 11,101–11,120 of 17,974 drug recalls

Drug Recall Terminated Historical recordClass II

Hydrocodone Bitartrate and Acetaminophen Oral Solution, 7.5 mg/325 mg per 15 mL C-II, a) 4 fl.oz .(120 mL), 12 bottles per case (NDC 66689-023-04), b) 16 fl.oz. (473 mL), 12 bottles per case (NDC 66689-023-16), c) 50 unit dose cups of 15 mL per case, (NDC No. 66689-023-50), Rx only, Manufactured by VistaPharm, Largo, FL 33771

by VistaPharm, Inc.

Reason
CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.
Recall initiated
January 18, 2017
Reported by FDA
February 8, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Nystatin Oral Suspension, USP 100,000 units per mL, a) 2 fl. oz. (60 mL), 24 bottles per case (NDC 66689-008-02), b) 16 fl. oz. (237 mL), 12 bottles per case (NDC 66689-008-16), Rx only, Manufactured by VistaPharm, Largo, FL 33771

by VistaPharm, Inc.

Reason
CGMP Deviations: Purified water used to manufacture the drug products may have been contaminated with Burkholderia cepacia.
Recall initiated
January 18, 2017
Reported by FDA
February 8, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

MIDAZOLAM INJECTION, USP, *25 mg/5 mL, (5 mg/ mL), 5 mL vials, 10 Vials per carton, Rx only, APP Pharmaceuticals, LLC Schaumburg, IL 60173 --- NDC 63323-412-05

by Fresenius Kabi USA, LLC

Reason
Failed Impurities/Degradation Specifications
Recall initiated
December 16, 2016
Reported by FDA
February 8, 2017
Distribution
Nationwide and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass II

Sun Pharma Carbidopa and Levodopa Tablets USP 25 mg/250 mg a) 100-count bottles (NDC 62756-519-88), b) 500-count bottles (NDC 62756-519-13) Rx Only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway, Halol-389 350 Gujarat, India.

by Sun Pharmaceutical Industries, Inc.

Reason
Failed Dissolution Specifications
Recall initiated
January 12, 2017
Reported by FDA
February 8, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

Endure 400 Scrub-Stat (chlorhexidine gluconate) Foam Forming Solution, 4%, packaged in plastic (HDPE) bottles, Over-the-counter, Model Number: 61430436 (800 mL, 12 bottles/case) - United States; Model Number: 6000179 (800 mL, 12 bottles/case) - Canada, Ecolab, St. Paul, MN 55102, NDC 47593-265-36

by Ecolab, Inc.

Reason
Subpotent Drug
Recall initiated
December 2, 2016
Reported by FDA
February 8, 2017
Distribution
United States, Puerto Rico and Canada

View recall →

Drug Recall Terminated Historical recordClass III

Finasteride Tablets, USP 5 mg, 90-count bottles, Rx only, Manufactured for : Camber Pharmaceuticals, Inc. Piscataway, NJ 08854 By: Hetero Hetero Labs, Unit V Polepally, Jadcheria, Mahaboob Nagar - 509 301, India Limited NDC 31722-525-90

by Hetero Drugs Ltd. - Unit 1

Reason
Failed Tablet/Capsule Specification: Tablets were found to be twice the thickness in one lot of product.
Recall initiated
December 29, 2016
Reported by FDA
February 8, 2017
Distribution
NJ only.

View recall →

Drug Recall Terminated Historical recordClass II

Flucanozole Tablets, USP, 200 mg, a) 30 count (NDC 55111-146-30) and b) 100 count (NDC 55111-146-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India

by Dr. Reddy's Laboratories, Inc.

Reason
Failed Dissolution Specifications; 18 month stability time point
Recall initiated
December 28, 2016
Reported by FDA
February 8, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Flucanozole Tablets, USP, 150 mg, 12x1 Blister cards, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India --- NDC 55111-145-12

by Dr. Reddy's Laboratories, Inc.

Reason
Failed Dissolution Specifications; 18 month stability time point
Recall initiated
December 28, 2016
Reported by FDA
February 8, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Flucanozole Tablets, USP, 100 mg, a) 30 count (NDC 55111-144-30) and b) 100 count (NDC 55111-144-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India

by Dr. Reddy's Laboratories, Inc.

Reason
Failed Dissolution Specifications; 18 month stability time point
Recall initiated
December 28, 2016
Reported by FDA
February 8, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Flucanozole Tablets, USP, 50 mg, a) 30 count (NDC 55111-143-30) and b) 100 count (NDC 55111-143-01) bottles, Rx Only, Mfd. by: Dr. Reddy's Laboratories, Bachupally 500 090 India

by Dr. Reddy's Laboratories, Inc.

Reason
Failed Dissolution Specifications; 18 month stability time point
Recall initiated
December 28, 2016
Reported by FDA
February 8, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

Azelastine Hydrochloride Nasal Solution (Nasal Spray), 0.1% (137 mcg per spray), packaged in 30 mL bottles, Rx only, Distributed by: West-Ward Pharmaceuticals Corp., Eatontown, NJ 07724, NDC 0054-0293-99

by Roxane Laboratories, Inc.

Reason
Defective Delivery System: out of specification result for droplet size distribution at the d90 measurement testing during the 6 month time point..
Recall initiated
December 14, 2016
Reported by FDA
February 1, 2017
Distribution
Nationwide and Puerto Rico.

View recall →

Drug Recall Terminated Historical recordClass II

Mesalamine, U.S.P. [CAS 89-57-6] Cambrex Charles City, Inc. Charles City, IA packaged in double lined PE liners inside Poly-lined cardboard drums. Net weight 40 kg

by Cambrex Charles City Inc

Reason
Presence of Particulate Matter: Stainless steel in a chemical reactor dissolved into the API solution and was detected in the finished product.
Recall initiated
May 20, 2014
Reported by FDA
February 1, 2017
Distribution
Product distributed solely to the state of Minnesota.

View recall →

Drug Recall Terminated Historical recordClass III

buPROPion Hydrochloride Extended-release Tablets, USP (SR), 200 mg, 60 count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India NDC 47335-0738-86

by Sun Pharmaceutical Industries, Inc.

Reason
Failed Dissolution Specifications; 18 month stability time point
Recall initiated
December 20, 2016
Reported by FDA
February 1, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

buPROPion Hydrochloride Extended-release Tablets, USP (SR), 150 mg, a) 60 (NDC 47335-737-86), b) 100 (NDC 47335-737-88) and c) 500 (NDC 47335-737-13) count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Ind. Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India

by Sun Pharmaceutical Industries, Inc.

Reason
Failed Dissolution Specifications; 18 month stability time point
Recall initiated
December 20, 2016
Reported by FDA
February 1, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Temozolomide Capsules, 250 mg, 5-count bottles, Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA, NDC 0378-5265-98.

by Mylan LLC.

Reason
Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
Recall initiated
December 20, 2016
Reported by FDA
February 1, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Temozolomide Capsules, 180 mg, packaged in a) 5-count bottles (NDC 0378-5264-98), b) 14-count bottles (NDC 0378-5264-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.

by Mylan LLC.

Reason
Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
Recall initiated
December 20, 2016
Reported by FDA
February 1, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Temozolomide Capsules, 140 mg, packaged in a) 5-count bottles (NDC 0378-5263-98), b) 14-count bottles (NDC 0378-5263-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.

by Mylan LLC.

Reason
Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
Recall initiated
December 20, 2016
Reported by FDA
February 1, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Temozolomide Capsules, 100 mg, packaged in a) 5-count bottles (NDC 0378-5262-98), b) 14-count bottles (NDC 0378-5262-14), Rx only, Mylan Pharmaceuticals, Inc., Morgantown, WV 26505 USA.

by Mylan LLC.

Reason
Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.
Recall initiated
December 20, 2016
Reported by FDA
February 1, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Amoxicillin for Oral Suspension USP, 125 mg per 5 mL, packaged in a 100 mL bottle, Rx only, Manufactured for: TEVA PHARMACEUTICALS USA, Sellersville, PA 18960, NDC 0093-4150-73

by Teva Pharmaceuticals USA

Reason
Subpotency: due to a low, out of specification test result for assay during stability testing.
Recall initiated
December 21, 2016
Reported by FDA
February 1, 2017
Distribution
United States and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass III

Albuterol Sulfate Inhalation Solution, USP, 0.021% (0.63 mg / 3 mL), 3mL Vials, Rx only, Mfd. for Watson Laboratories Inc., Corona, CA 92880 USA, Mfd. by Cipla Ltd. Verna, Goa India, NDC 0591-3467-53

by Actavis Inc

Reason
Failed Impurities/Degradation Specifications: Product is out of specification for a known degradant.
Recall initiated
January 12, 2017
Reported by FDA
February 1, 2017
Distribution
Nationwide in the US

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.